Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Sensei Biotherapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-18).
- Leadership changes: the latest reported is Karen Vousden, Director (Form 8-K filed 2026-09-17). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vk Services, LLC (filed 2026-08-14).
Who is behind it
Faeth Therapeutics, Inc.: incorporated in Delaware; business address in Austin, Texas; industry Pharmaceutical Preparations (Form D, 2026-09-17).
Officers and directors, each with the role and the filing that names them:
- Christopher Gerry: Executive Officer, Director (Form D, 2026-03-04)
- Josiah Craver: Executive Officer (Form D, 2026-03-04)
- Tom Ricks: Director (Form D, 2026-03-04)
- Anand Kiran Parikh: Executive Officer, Director (Form D, 2026-03-04)
- Phillip B. Donenberg: Director (Form D, 2026-03-04)
- Bob Holmen: Director (Form D, 2026-03-04)
- Kristian Humer: Director (Form D, 2026-03-04)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Trails Edge Capital Partners, LP | 2% |
| Schedule 13G, 2026-08-14 | Vk Services, LLC | 10.2% |
| Schedule 13G/A, 2026-08-14 | Caligan Partners LP | 2.4% |
| Schedule 13G/A, 2026-08-14 | Stempoint Capital LP | 0% |
| Schedule 13G, 2026-06-23 | S2g Investments, LLC | 9.99% |
| Schedule 13G, 2026-06-23 | Suvretta Capital Management, LLC | 7.8% |
| Schedule 13G/A, 2026-06-03 | Ics Opportunities Ii LLC | 3.1% |
| Schedule 13G, 2026-05-15 | Caligan Partners LP | 9.4% |
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-17 | Karen Vousden | Director | appointed | |
| Form 8-K, 2026-09-17 | Karen Vousden | appointed | ||
| Form 8-K, 2026-06-15 | Anand Parikh | President and Chief Executive Officer | appointed | 2026-06-13 |
| Form 8-K, 2026-06-15 | Brian Stephenson | Chief Financial Officer | appointed | 2026-06-13 |
| Form 8-K, 2026-04-16 | Stephen M. Hahn | Director | appointed |
Money raised
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-03-04 | $348.91M | $348.91M |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-02-18).
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
Permanent URL:
https://mentionfox.com/who-owns/faeth-therapeuticsLast updated 2026-10-18
Primary record: Schedule 13G, 2026-08-14 · Form D, 2026-03-04 · Form 8-K, 2026-09-17 · Form 8-K, 2026-06-15
Who owns Faeth Therapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-10-18. https://mentionfox.com/who-owns/faeth-therapeutics